Literature DB >> 16460778

Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Véronique Zennou1, Paul D Bieniasz.   

Abstract

APOBEC3G and APOBEC3F exhibit antiretroviral activity primarily as a consequence of their ability to deaminate cytidines in retroviral DNA. Here, we compare the properties of APOBEC3F and APOBEC3G from human, macaque, and African green monkey (AGM). While all APOBEC proteins tested exhibited anti-HIV-1 activity, human APOBEC3F was, surprisingly, 10- to 50-fold less potent than human APOBEC3G. However, similar discrepancies in antiviral potency were not found when pairs of proteins from macaque and AGM were compared. Intrinsic differences in the ability of each APOBEC protein to induce hypermutation, rather than differences in packaging efficiency, partially accounted for variable antiretroviral activity. Each of four primate lentivirus Vif proteins reduced human and AGM APOBEC3F expression and antiviral activity, but all were only partially effective and species-specific effects were relatively minor. Overall, highly efficient and species-specific neutralization of APOBEC3G, and less efficient neutralization of APOBEC3F, appears to be a general property of Vif proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16460778     DOI: 10.1016/j.virol.2005.12.035

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  70 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

3.  A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.

Authors:  John S Albin; Rebecca S LaRue; Jessalyn A Weaver; William L Brown; Keisuke Shindo; Elena Harjes; Hiroshi Matsuo; Reuben S Harris
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

4.  Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.

Authors:  Judd F Hultquist; Joy A Lengyel; Eric W Refsland; Rebecca S LaRue; Lela Lackey; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

5.  Chandipura virus induces neuronal death through Fas-mediated extrinsic apoptotic pathway.

Authors:  Sourish Ghosh; Kallol Dutta; Anirban Basu
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

6.  Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins.

Authors:  Cesar A Virgen; Theodora Hatziioannou
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 7.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

Review 8.  How HIV-1 Gag assembles in cells: Putting together pieces of the puzzle.

Authors:  Jaisri R Lingappa; Jonathan C Reed; Motoko Tanaka; Kasana Chutiraka; Bridget A Robinson
Journal:  Virus Res       Date:  2014-07-24       Impact factor: 3.303

9.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.

Authors:  Andrew E Armitage; Aris Katzourakis; Tulio de Oliveira; John J Welch; Robert Belshaw; Kate N Bishop; Beatrice Kramer; Andrew J McMichael; Andrew Rambaut; Astrid K N Iversen
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.